FDA Approves Zactima

Publication
Article
Oncology & Biotech NewsDecember 2010
Volume 4
Issue 12

An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease.

An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease. The panel expressed concerns about “substantial” drug-related toxicity associated with the 300-mg daily dose. Members said that patients taking Zactima appeared to be at greater risk for stroke and other cerebrovascular events and a prolonged QT interval.

Related Videos
Bernard A. Fox, PhD
Jameel Muzaffar, MD
Deborah J. Wong, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Anna Lee, MD, MPH
Julien Hadoux, MD, PhD, medical oncologist, attending physician, Gustave Roussy, Villejuif, France
David Sher, MD
Nabil F. Saba, MD, FACP
Jun Ma, MD
Bernard Doger de Spéville, MD, PhD